For the quarter ending 2026-03-31, ENZN has $428,874K in assets. $28,619K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 28,619 | 42,574 | 43,256 | 44,294 |
| Receivables, net | 62,833 | - | - | - |
| Inventories, net | 98,846 | - | - | - |
| Other current assets | 44,283 | 239 | 411 | 444 |
| Total current assets | 234,581 | 42,813 | 43,667 | 44,738 |
| Property, plant and equipment | 485,501 | - | - | - |
| Less accumulated depreciation | 342,550 | - | - | - |
| Property, plant and equipment, net | 142,951 | - | - | - |
| Right of use assets | 18,806 | - | - | - |
| Other assets, net | 10,667 | - | - | - |
| Intangible assets, net | 12,894 | - | - | - |
| Goodwill | 3,073 | - | - | - |
| Deferred tax asset | 5,902 | - | 26 | 42 |
| Total assets | 428,874 | 42,813 | 43,693 | 44,780 |
| Short-term debt | 51,104 | - | - | - |
| Accounts payable | 36,893 | 331 | 331 | 331 |
| Accrued liabilities | 24,792 | 400 | 209 | 472 |
| Short-term lease liabilities | 4,148 | - | - | - |
| Total current liabilities | 116,937 | 731 | 540 | 803 |
| Long-term debt, net of current maturities | 79,730 | - | - | - |
| Accrued employee benefits | 22,621 | - | - | - |
| Deferred income taxes | 1,495 | - | - | - |
| Long-term lease liabilities | 16,973 | - | - | - |
| Series c preferred stock - 0.01 par value, 40,000 shares authorized, issued and outstanding (liquidation value 1,115 per share and 1,062 per share) at december 31, 2025 and 2024, respectively-Series CPreferred Stock | - | 44,607 | 44,076 | 43,545 |
| Series c preferred stock - 0.01 par value, 3,000,000 shares authorized, 384 and 0 issued and outstanding (liquidation value 1,129 and 0 per share) at march 31, 2026 and december 31, 2025, respectively | 433 | - | - | - |
| Common stock, 0.01 par value 170,000,000 shares authorized, 14,371,173 shares issued and 14,331,620 shares outstanding at march 31, 2026 and 170,000,000 shares authorized 6,651,652 shares issued and 6,612,099 shares outstanding at december 31, 2025 | 143 | 742 | 742 | 742 |
| Paid in capital | 267,959 | 70,034 | 70,565 | 71,096 |
| Retained earnings | -18,570 | -73,301 | -72,230 | -71,406 |
| Accumulated other comprehensive loss | -57,331 | - | - | - |
| Total viskase stockholders' equity | 192,201 | -2,525 | -923 | 432 |
| Deficit attributable to non-controlling interest | -1,516 | - | - | - |
| Total stockholders' equity | 190,685 | - | - | - |
| Total liabilities, mezzanine equity, and stockholders' equity | 428,874 | 42,813 | 43,693 | 44,780 |
ENZON PHARMACEUTICALS, INC. (ENZN)
ENZON PHARMACEUTICALS, INC. (ENZN)